Biogen Inc.

BIIB · Nasdaq · ·

Сравнить

253,51 $+1,2 %закрытие 13 нояб.

Данные по 30 сентября 2026 г., из отчёта 10-Q, поданного 28 октября 2026 г.

1W: +2,1 %
1M: +8,9 %

Акции Biogen Inc. (BIIB) — это хороший бизнес? — InspectStocks

Biogen Inc.

BIIB · Nasdaq · ·

Сравнить

253,51 $+1,2 %закрытие 13 нояб.

Данные по 30 сентября 2026 г., из отчёта 10-Q, поданного 28 октября 2026 г.

1W: +2,1 %
1M: +8,9 %

Just reported

Q3 2026 results

From Biogen's results release of 28 октября 2026 г.; its quarterly report has since been filed.

Revenue
Actual
2,8B $
+11 % y/y
+2,5 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,14 $
Guided
—
No guide given

Company outlook

Full year 2026

EPS, adjusted12,20 $ – 13,00 $First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Подборка
Biotech
От InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Цена, 1 год
+26,8 %
Выручка, 1 год
+12,9 %
+13
A 8B 4C 5D 1F 1

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

На чём зарабатывает

Sales of prescription medicines72 %
Anti-CD20 medicine royalties and profit shares18 %
Contract manufacturing, royalties and related revenue8 %
Alzheimer’s medicine collaboration2 %

Доли выручки — это оценки за nine months ended September 30, 2026, а не цифры из поданной отчётности.

Конкурирует с

LLYEli Lilly and Company
A
Размер
1,36T $
Маржа
31,9 %
RHHBYRoche Holding AG
NVSNovartis AG
A
Размер
306,3B $
Маржа
-0,1 %

Что продаёт6

SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.

Показать ещё 3

SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.

Кто покупает4

Wholesale distributors buy medicines in bulk for resale; a pair of distributors together accounted for 43.9% of gross product revenue (FY 2025, high).
Specialty pharmacies and specialty distributors handle medicines that require specific storage, delivery or patient support.
Hospitals, clinics and physicians prescribe or administer Biogen medicines and help patients obtain them.
Government health programs and private insurers cover or reimburse the cost of many treatments.

На чём держится и что может это сломать

От чего зависит бизнес

1Biogen relies on collaborators for some medicines’ development, manufacturing or sales, including Eisai, Ionis, Genentech, Supernus and Samsung Bioepis.
2A pair of wholesale distributors accounted for 43.9% of gross product revenue (FY 2025, high).
3Sales depend on regulatory approval, continued patent or other market protection, and coverage and reimbursement from government programs and private insurers.

Что может пойти не так

1Generic and biosimilar medicines, as well as newer competing treatments, can reduce sales or prices; generic versions of TECFIDERA and a biosimilar version of TYSABRI already compete with those products.
2Clinical studies can fail, take longer than planned or lead regulators to reject a medicine, limiting revenue from new products and additional uses of existing medicines.
3Changes to drug-price rules, insurance coverage or reimbursement can restrict patient access or lower the amount Biogen receives for its medicines.

Полная финансовая отчётность →

О компании Biogen Inc.

Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.

Штаб-квартира: Cambridge, Massachusetts
Год основания: 1978
Торгуется на: NASDAQ
Конец финансового года: December 31

Построено по собственной отчётности Biogen Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.

Just reported